The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
The following is a summary of "Emergent Pericardial Window in a Patient with Sarcoidosis-like Interstitial Lung Disease, COPD ...
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Sleep apnoea devices giant ResMed has laid out an ambitious growth strategy aiming to broaden its product lines and notch up ...
Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...
One of the most deprived places in the country hopes to be "smoke free" by 2030 as Knowsley Council aims to reduce smoking ...
A National Institute for Health and Care Research (NIHR) evidence collection brings together research on whether stratified care can help primary care teams manage long-term conditions. Stratified ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback